newsfilter
← Latest News
Business Wire·

Ambrx Announces NovoCodex's Dosing of First Patient with ARX305, Ambrx's Investigational Antibody Drug Conjugate Targeting CD70

- ARX305 is being evaluated by Ambrx's partner, NovoCodex, in a Phase 1 clinical trial in various advanced tumors - - First patient dosing triggers milestone payment to Ambrx - - NovoCodex responsible for funding